

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- 1.-23. (Cancelled).
24. (Previously Presented) A humanized antibody binding to CD47, comprising:
 - (1) a heavy chain variable region containing the sequence of aa 1-117 of SEQ ID NO: 99; and
 - (2) a light chain variable region containing the sequence of aa 1-112 of SEQ ID NO: 106.
25. (Currently Amended) The humanized antibody of claim ~~[[23]]~~ 24, wherein:
 - (i) Gly 44 of SEQ ID NO: 99 is replaced with Cys, and Gln 105 of SEQ ID NO: 106 is replaced with Cys,
 - or
 - (ii) Gln 109 of SEQ ID NO: 99 is replaced with Cys and Ser 48 of SEQ ID NO: 106 is replaced with Cys

~~the sequence of aa 40-54 (FR2) of SEQ ID NO: 106 is replaced with the sequence of aa 159-175 (FR2) of SEQ ID NO: 92.~~
26. (Cancelled).
27. (Currently Amended) The humanized antibody of ~~any one of claims~~ claim 24, which is a small antibody fragment containing an antigen-binding domain.
28. (Cancelled).
29. (Previously Presented) The humanized antibody of claim 27, which is a diabody.
30. (Cancelled).

31. (Previously Presented) The humanized antibody of claim 29, which is a single-chain diabody.

32. (Cancelled).

33. (Previously Presented) The humanized antibody of claim 27, wherein a disulfide bond exists between diabody-forming fragments.

34.-37. (Cancelled).

38. (Previously Presented) An antibody binding to CD47, comprising any one of:

(1) the sequence of aa 1-234 of SEQ ID NO: 110; and

(2) the sequence of aa 1-483 of SEQ ID NO: 113.

39. (Cancelled).

40. (Previously Presented) A therapeutic agent for a hematological disorder, comprising a therapeutically effective amount of the antibody of claim 24 and a pharmaceutically acceptable carrier.

41. (Previously Presented) A therapeutic agent for a hematological disorder, comprising a therapeutically effective amount of the antibody of claim 38 and a pharmaceutically acceptable carrier.

42.-43. (Cancelled).

44. (New) The therapeutic agent of claim 40, wherein the hematological disorder is selected from leukemias such as acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma, aplastic anemia, myelodysplastic syndromes, and polycythemia vera.

45. (New) The therapeutic agent of claim 41, wherein the hematological disorder is selected from leukemias such as acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma, aplastic anemia, myelodysplastic syndromes, and polycythemia vera.